GHK-Cu 50mg — Vial Spec, Reconstitution Math & COA

Overview of GHK-Cu 50mg Lyophilized Specification

A 50mg vial specification of GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex) represents a high-capacity bulk unit tailored for laboratory research environments conducting extended in vitro series or multi-subject animal models. Each vial contains 50 milligrams of highly purified copper peptide complex presented as a lyophilized blue cake, vacuum-sealed under an inert atmosphere to prevent moisture sorption and oxidative degradation. This specific mass threshold allows investigative teams to prepare uniform master stock solutions without the inter-vial batch variation associated with reconstituting multiple lower-mass units.

Principal investigators and laboratory managers typically select a 50mg footprint when designing protocols requiring constant, high-concentration cellular exposure, high-frequency topical assays, or large-sample microplate evaluations. If your ongoing experimental design calls for smaller exploratory footprints, PX1 Research provides standard unit sizes within our main catalog of research peptides. Researchers seeking high-capacity 50mg configurations or custom batch runs for institutional projects can coordinate fulfillment directly through our bulk institutional accounts portal. Regardless of the unit size selected, every vial is subject to rigorous lot-specific analytical verification before release.

Chemical Profile & Molecular Characteristics of GHK-Cu

GHK-Cu is a naturally occurring tripeptide-copper complex in which the amino acid sequence Glycyl-L-Histidyl-L-Lysine coordinates tightly with a divalent copper ion ($Cu^{2+}$). The coordination geometry involves nitrogen atoms from the histidine imidazole ring, the alpha-amine group of glycine, and peptide backbone amide nitrogens. This specific chelation geometry stabilizes the copper center, modulating its redox reactivity and facilitating specific binding interactions with cell-surface receptors, integrins, and extracellular matrix (ECM) components.

In chemical literature, GHK-Cu exhibits a molecular formula of $C_{14}H_{23}CuN_6O_4$ and a molecular weight of approximately 404.93 g/mol (for the standard complex free base). The deep blue coloration characteristic of high-purity GHK-Cu stems from $d-d$ electron transitions within the hexacoordinated or pentacoordinated $Cu^{2+}$ center. Preclinical data indicate that the biological activity of the compound is strictly dependent on maintaining intact copper chelation. Standard assay protocols evaluate both total peptide purity via High-Performance Liquid Chromatography (HPLC) and elemental copper stoichometry via Mass Spectrometry (MS) or Inductively Coupled Plasma Mass Spectrometry (ICP-MS) to ensure baseline consistency.

Reconstitution Math: Volumetric Calculations for 50mg Vials

Reconstituting a 50mg lyophilized cake requires accurate volumetric calculations to ensure precise stock concentrations for downstream laboratory applications. Depending on the assay requirements, researchers generally utilize sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile isotonic saline as the solvent. When adding solvent, liquid should be directed down the glass vial wall rather than directly onto the lyophilized cake to prevent shear stress and excessive foaming.

The mathematical formula to calculate concentration ($C$) is given by $C = m / V$, where $m$ is the mass of the peptide (50 mg) and $V$ is the volume of reconstituting solvent added in milliliters (mL):

1. Reconstitution with 1.0 mL diluent: Yields a stock concentration of 50.0 mg/mL (equivalent to 50.0 µg/µL or 5.0% w/v). This highly concentrated stock solution is ideal for high-yield master aliquots requiring minimal liquid transfer volumes.

2. Reconstitution with 2.0 mL diluent: Yields a stock concentration of 25.0 mg/mL (equivalent to 25.0 µg/µL or 2.5% w/v). This intermediate concentration provides enhanced pipetting control for microplate assays.

3. Reconstitution with 3.0 mL diluent: Yields a stock concentration of 16.67 mg/mL (equivalent to 16.67 µg/µL or ~1.67% w/v). This dilution reduces solution viscosity and allows for granular volumetric delivery across sub-centimeter plate wells.

For custom concentration targets or automated volumetric adjustments across varying laboratory container formats, researchers are encouraged to utilize our interactive reconstitution calculator to eliminate manual conversion errors prior to bench preparation.

Preclinical Research Focus: Extracellular Matrix & Collagen Synthesis

In vitro and animal model studies demonstrate that GHK-Cu plays a central regulatory role in extracellular matrix (ECM) homeostasis. Preclinical assays utilizing cultured dermal fibroblasts show that exposure to GHK-Cu upregulates the transcription and secretion of Type I and Type III collagen, as well as tropoelastin. These structural proteins form the scaffold of mammalian connective tissue, providing tensile strength, elasticity, and structural integrity.

Furthermore, research indicates that GHK-Cu modulates the production of glycosaminoglycans (GAGs) such as dermatan sulfate and chondroitin sulfate, along with small leucine-rich proteoglycans like decorin. Decorin plays a crucial role in directing procollagen molecules into uniform fibrils, thereby improving matrix organization. Investigational models assessing ECM biosynthesis frequently quantify changes in procollagen mRNA expression via quantitative Real-Time PCR (qPCR) and measure total collagen deposition through hydroxyproline quantification or Western blotting assays.

Wound Closure Models and Fibrotic Scarring Mitigation

Beyond baseline matrix deposition, GHK-Cu has been extensively evaluated in preclinical models of tissue repair and wound closure. In rodent dermal injury assays, localized application of GHK-Cu accelerates re-epithelialization, increases granulation tissue formation, and enhances neovascularization at the injury site. The peptide complex promotes chemoattraction of macrophages and mast cells during early inflammatory phases, facilitating rapid clearance of cellular debris.

Crucially, GHK-Cu is studied for its capacity to prevent excessive fibrotic scarring. In vitro data indicate that while GHK-Cu stimulates early collagen production, it simultaneously modulates Transforming Growth Factor-beta (TGF-β) signaling pathways. By balancing pro-fibrotic signaling with increased expression of Matrix Metalloproteinases (MMP-1 and MMP-2) and suppressing Tissue Inhibitors of Metalloproteinases (TIMPs), GHK-Cu fosters an environment conducive to functional matrix remodeling rather than disorganized, dense scar tissue formation. Researchers investigating dermal repair mechanism can access supporting documentation in our peptide research library.

Comparative Analysis: GHK-Cu vs. Matrix-Active Research Compounds

When designing tissue repair and cellular remodeling protocols, investigators often compare GHK-Cu against other prominent matrix-modifying research peptides. Key compounds operating within similar experimental models include BPC-157, a synthetic pentadecapeptide investigated for focal adhesion kinase activation and cytoprotection, and TB-500, a synthetic fragment of thymosin beta-4 studied for actin sequestration and cell migration.

While BPC-157 and TB-500 predominantly target cell survival, angiogenic signaling cascades, and cytoskeleton dynamics, GHK-Cu is unique in its direct copper-mediated modulation of gene expression related to matrix turnover and remodeling. In many comparative rodent protocols, researchers analyze whether combining copper peptides with cytoprotective peptides yields additive effects on collagen cross-linking and wound tensile strength versus individual administration. For a broader overview of related target profiles, consult our main GHK-Cu standard catalog items page.

Analytical Verification: HPLC, Mass Spectrometry, and Endotoxin Limits

To maintain analytical consistency across preclinical trials, PX1 Research enforces strict quality assurance criteria for every production lot. Every batch of GHK-Cu undergoes complete characterization within an ISO 17025 accredited laboratory utilizing high-performance liquid chromatography (HPLC) paired with electrospray ionization mass spectrometry (ESI-MS). The target purity threshold for PX1 research-grade peptides is established at $\ge 98.0\%$ by peak area integration.

Because GHK-Cu is routinely deployed in primary cell culture and sensitive in vivo models, endotoxin contamination presents a major confounding variable that can trigger non-specific inflammatory signaling. PX1 performs chromogenic Limulus Amebocyte Lysate (LAL) testing on every lot to guarantee endotoxin levels remain strictly below regulatory thresholds ($<0.05\text{ EU/mg}$). Researchers can independently verify batch purity, verified mass spectra, and endotoxin levels by inputting their lot number into our lot-specific COA database.

Aliquot Planning, Storage Protocols, and Cold-Chain Handling

Lyophilized GHK-Cu 50mg vials possess high thermal stability when stored dry under controlled conditions. Upon receipt, lyophilized vials should be maintained at $-20^\circ\text{C}$ for long-term storage (up to 24 months) or $2\text{--}8^\circ\text{C}$ for short-term usage (up to 90 days), shielded from direct light exposure. Maintaining a desiccated environment prevents premature hydrolytic degradation of the peptide chain.

Following reconstitution, liquid stock solutions must be handled with care to prevent loss of biological activity and copper dissociation:

1. Temperature Control: Reconstituted liquid stock should be stored at $2\text{--}8^\circ\text{C}$ and utilized within 3 to 4 weeks. For longer preservation, freeze working stock into single-use aliquots at $-80^\circ\text{C}$.

2. Aliquot Planning: To avoid repeated freeze-thaw cycles—which degrade peptide bonds and disrupt metal coordination—divide reconstituted stock into small single-use volumes (e.g., 100 µL to 500 µL) in sterile, low-binding microcentrifuge tubes.

3. Buffer Avoidance: Avoid reconstituting or diluting directly into solutions containing strong chelating agents (such as EDTA) or excessive reducing agents (such as DTT), as these can strip the copper ion from the peptide core.

Selecting the Optimal Mass Specimen: 20mg vs. 50mg Fill Sizes

Selecting the appropriate vial mass depends on experimental scale, sample size, and duration of the study. While a 50mg vial offers economic and operational advantages for high-throughput screening, lower-volume research may be better served by standard 20mg specifications to minimize open-vial duration and waste.

For small-scale exploratory assays involving limited cell lines or short-duration microplate studies, smaller mass footprints prevent unused reconstituted liquid from undergoing prolonged storage degradation. Conversely, for large animal cohorts or high-concentration daily topical treatments over multi-week periods, a 50mg mass point ensures that all test subjects receive peptide from the identical analytical lot, eliminating batch-to-batch variation. For additional guidance on selecting compound formats for your facility, review our GHK-Cu research literature or contact our technical support team.